Sign in
WithdrawnNo phase

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia

Key facts

Who runs it
UNC Lineberger Comprehensive Cancer Center
Where
Chapel Hill, United StatesSee the site
Trial code
Status
Withdrawn
Started
8 Aug 2025
Expected to end
Jan 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • standard radiotherapy
  • experimental radiotherapy
Record updated
5 September 2025
Why it stopped
Operational reason

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information
  • Subjects is willing and able to comply with study procedures based on the judgment of the investigator
  • Age ≥ 18 years at the time of consent
  • T0-4, N0-3, M0 disease American Joint Committee on Cancer (AJCC 7th or 8th edition) of the oropharynx (this includes patients with head and neck cancer of unknown primary origin, often categorized as T0 disease, who will be treated with radiotherapy to the oropharynx) planned for definitive radiotherapy +/- chemotherapy; 5 No contraindications to receiving MRI such as implanted electrical devices, pregnancy, and significant quantities of metal in the head/neck

Who cannot take part

  • Prior history of radiation therapy to the head and neck
  • Patients with Sjogren's syndrome or baseline xerostomia (CTCAE > 0 for the question regarding dry mouth)
  • Patients with an allergy to lemon juice
  • Patients with lesions grossly involving the salivary glands

Other criteria

  • In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Eligibility must be maintained up for the subject to be considered eligible for treatment

Where in United States

  • University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel Hill, United States

About the trial

What the trial wants to find out

Radiation-induced xerostomia (dry mouth) is one of the most common and severe toxicities experienced by patients undergoing radiation treatment for head and neck cancer. Radiation-induced dry mouth is a frequently experienced symptom and persists after treatment, potentially indefinitely. Current practice does not specifically attempt to spare the parotid ducts, where stem/progenitor cells are believed to preferentially reside, and considers the entire salivary gland to have equal function. New radiation therapy planning and conducting strategies are needed to reduce this toxicity and maximize patient quality of life post-treatment.

Read full original descriptionShow less

This randomized Phase II study explores the contribution of magnetic resonance imaging (MRI) guided salivary gland duct definition to decrease patient-reported xerostomia in patients with oropharynx cancer receiving radiation therapy. The severity of xerostomia will be measured by patient-reported (PRO) symptoms, saliva secretion, saliva pH, and buffering.

The 2 groups in the trial

  • Mean ParotidExisting treatment, for comparison

    Standard radiotherapy planning aims to restrict the mean parotid radiation dose to less than or equal to 14 Gy.

    Treatment: standard radiotherapy

  • Parotid DuctTreatment being tested

    Magnetic resonance images will be used to localize the parotid ducts and limit the radiation dose to these structures to less than or equal to 14 Gy.

    Treatment: experimental radiotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Assessment of Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia Following Radiotherapy for Oropharynx Cancer
Record updated
5 September 2025